# 510(k) Summary

LIPOSCIENCE

A. 510(k) Number: K113830 B. Submitter Contact Information:

# Submitter:

LipoScience, Inc. 2500 Sumner Boulevard Raleigh, NC 27616 Ph: (919) 256-1326 Fax: (919) 256-1149

# Contact Person:

Suzette Warner   
Manager, Regulatory Affairs   
LipoScience, Inc.   
Ph: (919) 256-1326   
Fax: (919) 256-1149   
Suzette.Warner@liposcience.com

# C. Device Name:

Trade Name: Vantera® Clinical Analyzer   
Common Name: NMR LipoProfile® test on Vantera® Clinical Analyzer   
Classification Names:

Instrumentation for clinical multiplex test system, 21 CFR 862.2570, Product Code NSU Lipoprotein test system, 21 CFR 862.1475, Product Code MRR and LBS Cholesterol test system 21 CFR 862.1175, Product Code LBS Triglyceride test system, 21 CFR 862.1705, Product Code CDT

Panel: Clinical Chemistry (75)

# D. Legally Marketed Device to which Equivalence is Claimed (Predicate Device):

NMR Profiler and NMR Lipoprofile test k111516   
Luminex LX 100/200 Instrument k073506

# E. Device Description:

# For the Instrument

The Vantera Clinical Analyzer is a clinical laboratory analyzer that employs nuclear magnetic resonance spectroscopic detection to quantify multiple analytes in biological fluid specimens, specifically blood plasma and serum.

The Vantera Clinical Analyzer system design is divided into 3 major subassemblies: a sample handling assembly, an NMR subassembly, and an enclosure. The Vantera Clinical Analyzer control system is distributed across three separate computers:

− The Host (1U) controls user interface, data handling, results calculation, system startup and shutdown.   
• The Process Control (4U) schedules and manages all activities required to process a sample, controls all hardware in the sample handling subsystem, and manages remote access to the system.   
• The NMR Control Computer controls all magnet operations. Two of these computers are contained within the Sample Handling Subassembly (1U and 4U) and one in the NMR Subassembly (NMR Console).

# For the Assay

The NMR LipoProfile test involves measurement of the $4 0 0 ~ \mathrm { M H z }$ proton NMR spectrun of a plasma/serum sample, deconvolution of the composite signal at approximately 0.8 ppm to produce signal amplitudes of the lipoprotein subclasses that contribute to the composite plasma/serum signal, and conversion of these subclass signal amplitudes to lipoprotein subclass concentrations. The ${ \sim } 0 . 8$ ppm plasma NMR signal arises from the methyl group protons of the lipids carried in the LDL, HDL and VLDL subclasses of varying diameters. The NMR signals from the various lipoprotein subclasses have unique and distinctive frequencies and lineshapes, each of which is accounted for in the deconvolution analysis model. Each subclass signal amplitude is proportional to the number of subclass particles emitting the signal, which enables subclass particle concentrations to be calculated from the subclass signal amplitudes derived from the spectral deconvolution analysis. LDL subclass particle concentrations, in units of nanomoles of particles per liter (nmol/L), are summed to give the reported total LDL particle concentration (LDL-P). By employing conversion factors assuming that the various lipoprotein subclass particles have cholesterol and triglyceride contents characteristic of normolipidemic individuals, HDL cholesterol and triglyceride concentrations are also derived.

# F. Indications for Use

# For the Instrument

The Vantera Clinical Analyzer is an automated laboratory test analyzer which measures the $4 0 0 ~ \mathrm { { M H z } }$ proton nuclear magnetic resonance (NMR) spectrum of clinical samples to produce signal amplitudes, converting these signal amplitudes to analyte concentration. The device includes a 400 MHz NMR spectrometer and software to analyze digitized spectral data. This instrumentation is intended to be used with NMR based assays to detect multiple analytes from clinical samples by technologists trained in laboratory techniques, procedures and on the use of the analyzer.

# For the Assay

The NMR LipoProfiletest, when used with the Vantera Clinical Analyzer, an automated NMR spectrometer, measures lipoprotein particles to quantify LDL particle number (LDL-P), HDL cholesterol (HDL-C), and triglycerides in human serum and plasma using nuclear magnetic resonance (NMR) spectroscopy. LDL-P and these NMR-derived concentrations of HDL-C and triglycerides are used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

# G. Technological Characteristics and Substantial Equivalence:

The Vantera Clinical Analyzer is as safe and effective as the predicate device, k073506. The Vantera has similar intended use and indication for use as well as the same multianalyte capability and the same system calibration requirement as the predicate device. The minor technological differences between the Vantera and the predicate device raise no new issues of safety or effectiveness.

# Instrument Comparison Table

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Luminex LX 100/200Instrument(Predicate)</td><td colspan="1" rowspan="1">Vantera Clinical Analyzer(Proposed Device)</td></tr><tr><td colspan="1" rowspan="1">510(k)Number</td><td colspan="1" rowspan="1">k073506</td><td colspan="1" rowspan="1">Pending</td></tr><tr><td colspan="1" rowspan="1">Intended Use /Indications forUse</td><td colspan="1" rowspan="1">The Luminex LX100/200 Instrument is aclinical multiplex testsystem intended tomeasure and sort multiplesignals generated in an InVitro diagnostic assayfrom a clinical sample.This instrumentation isused with a specific assayto measure multiplesimilar analytes thatestablish a singleindicator to aid indiagnosis. The deviceincludes a signal readerunit, raw data storagemechanisms, dataacquisition software andsoftware to processdetected signals.</td><td colspan="1" rowspan="1">similar</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Bead based multiplexing</td><td colspan="1" rowspan="1">Nuclear magneticresonance</td></tr><tr><td colspan="1" rowspan="1">Multi-Analyte</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">DetectionMethod</td><td colspan="1" rowspan="1">Fluorescent</td><td colspan="1" rowspan="1">400 MHz proton NMRSpectrum</td></tr><tr><td colspan="1" rowspan="1">SystemFluidics</td><td colspan="1" rowspan="1">Utilizes system fluidics todeliver sample to the siteof sample analysis</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">SpecimenSampling andHandling</td><td colspan="1" rowspan="1">Samples are manuallyprepared then presented tosystem.</td><td colspan="1" rowspan="1">Serum/Plasma Samples arediluted onboard system</td></tr><tr><td colspan="1" rowspan="1">SystemCalibration</td><td colspan="1" rowspan="1">System calibrationrequired</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">QualityControlChecks</td><td colspan="1" rowspan="1">System level qualitycontrol checks availablee.g. Classification (CON1)and reporter (CON2)</td><td colspan="1" rowspan="1">similarE.g. Signal to noise ratio -internal system check thatoccur during systemcalibration</td></tr><tr><td colspan="1" rowspan="1">SpecimenIdentification</td><td colspan="1" rowspan="1">Barcode reader entry ofsample ID</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">DataAcquisitionSoftware</td><td colspan="1" rowspan="1">Posses data acquisitionsoftware and software toprocess detected signals</td><td colspan="1" rowspan="1">same</td></tr></table>

# Similarity to the Predicate Device (Assay)

Performance data further demonstrate that the Vantera Clinical Analyzer when used with the NMR LipoProfile test is as safe and effective as its predicate device, k1 11516. As with the predicate test, the NMR LipoProfile test on Vantera is intended for the separation and quantification of LDL-P, HDL-C and triglycerides in serum and plasma, measurements of which are used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

# Assay General Attributes

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>LipoScienceNMR LipoProfile® testand NMR Profiler(Predicate)</td><td rowspan=1 colspan=1>Vantera® ClinicalAnalyzer for use withNMR LipoProfile® test(Proposed Device)</td></tr><tr><td rowspan=1 colspan=1>510(k)Number</td><td rowspan=1 colspan=1>k111516</td><td rowspan=1 colspan=1>Pending</td></tr><tr><td rowspan=1 colspan=1>Intended Use /Indications forUse</td><td rowspan=1 colspan=1>The NMR LipoProfiletest, used with the NMRProfiler, an automatednuclear magneticresonance (NMR)spectrometer, measureslipoprotein particles toquantify LDL particlenumber (LDL-P), HDLcholesterol (HDL-C), andtriglycerides in serumand plasma using NMRspectroscopy. LDL-Pand these NMR-derivedconcentrations oftriglycerides and HDL-Care used in conjunctionwith other lipidmeasurements andclinical evaluation to aidin the management oflipoprotein disordersassociated withcardiovascular disease.This test is performedand provided as a serviceby LipoScienceLaboratory.</td><td rowspan=1 colspan=1>similar</td></tr><tr><td rowspan=1 colspan=1>PatientPopulation</td><td rowspan=1 colspan=1>General</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>NMR Profiler</td><td rowspan=1 colspan=1>Vantera Clinical Analyzer</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Human serum and plasma</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>400 MHz NMRSpectrometer</td><td rowspan=1 colspan=1>same</td></tr></table>

Page 6.7   

<table><tr><td>Reagents and</td><td>LipoScience NMR LipoProfile® test and NMR Profiler (Predicate) NMR Diluent 1 - •</td><td>Vantera® Clinical Analyzer for use with NMR LipoProfile® test (Proposed Device) Similar</td></tr><tr><td>Materials</td><td>aqueous solution containing NaEDTA (5.0mM), CaCl (1.0mM), KCL(120mM), NaHPO4- 7H20(50mM), (50mM), pH 7.4, 6.0 M NaOH, 1.0 M HCI. NMR WASH- Triton X-100- 0.1%v/v, Liqui Nox 0.1% v/v in Type 2 water, pH 10.0, sodium bicarbonate (anhydrous), sodium carbonate (anhydrous), 6.0 M NaOH NMR Calibrator - • aqueous solution of Trimethyl Acetate (TMA) disodium salt (15.0 mM) containing NaEDTA (5.0 mM), CaC2 (3.0 mM), KCl (120</td><td></td></tr><tr><td></td><td>nM), DO 10% v/v NMR LipoProfile Quality Control materials 1 and 2 contains two levels of pooled human serum-based control material, labeled Control 1 and Control 2, with pre- determined target</td><td></td></tr><tr><td></td><td>ranges, containing sodium azide as a preservative.</td><td></td></tr></table>

Premarket Notification 510(kVantera® Clinical Analyzer or use with NMR Liporofile® test Section 6 - 510(k) Summary   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>LipoScienceNMR LipoProfile® testand NMR Profiler(Predicate)</td><td rowspan=1 colspan=1>Vantera® ClinicalAnalyzer for use withNMR LipoProfile® test(Proposed Device)</td></tr><tr><td rowspan=1 colspan=1>SpectralDeconvolutionComputationalProcess</td><td rowspan=1 colspan=1>Linear least-squareswith singular valuedecomposition of thespectra from eachspecimen.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReferenceRange</td><td rowspan=1 colspan=1>Distribution of LDL-PObserved in Referencepopulation - MESA</td><td rowspan=1 colspan=1>Distribution of LDL-Pobserved in a generalapparently healthypopulation of men andwomen</td></tr></table>

We performed analytical validations to demonstrate that the NMR LipoProfile $\textsuperscript { \textregistered }$ test on the Vantera Clinical Analyzer is equivalent to the NMR LipoProfile $\textsuperscript { \textregistered }$ test on the NMR Profiler. The comparative analytical performance is found in tables below.

Analytical Performance for LDL-P   

<table><tr><td rowspan=1 colspan=1>LDL-P (nmol/L)</td><td rowspan=1 colspan=3>Vantera clinical analyzerfor use with theNMR LipoProfile test</td><td rowspan=1 colspan=3>Predicate Device k111516</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>0</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=3>40.7</td><td rowspan=1 colspan=3>41</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=3>132</td><td rowspan=1 colspan=3>157</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=3>300-3500 nmol/L</td><td rowspan=1 colspan=3>300-3500 nmol/L</td></tr><tr><td rowspan=1 colspan=1>Linearity Regression</td><td rowspan=1 colspan=3>y=1.02x+7.82</td><td rowspan=1 colspan=3>y=0.99x-22.37</td></tr><tr><td rowspan=1 colspan=1>Linearity R2</td><td rowspan=1 colspan=3>0.9949</td><td rowspan=1 colspan=3>0.9979</td></tr><tr><td rowspan=1 colspan=1>Within-Run Precision</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>842.6</td><td rowspan=1 colspan=1>1309.5</td><td rowspan=1 colspan=1>1837.7</td><td rowspan=1 colspan=1>908</td><td rowspan=1 colspan=1>1493</td><td rowspan=1 colspan=1>1967</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>48.5</td><td rowspan=1 colspan=1>39.1</td><td rowspan=1 colspan=1>50.3</td><td rowspan=1 colspan=1>45.4</td><td rowspan=1 colspan=1>64.8</td><td rowspan=1 colspan=1>72.8</td></tr><tr><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>3.7%</td></tr><tr><td rowspan=1 colspan=1>Within-Lab Precision</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>988.6</td><td rowspan=1 colspan=1>1266.7</td><td rowspan=1 colspan=1>1943.5</td><td rowspan=1 colspan=1>920.4</td><td rowspan=1 colspan=1>1508.3</td><td rowspan=1 colspan=1>1991.8</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>48.84</td><td rowspan=1 colspan=1>32.57</td><td rowspan=1 colspan=1>63.42</td><td rowspan=1 colspan=1>70.5</td><td rowspan=1 colspan=1>67.7</td><td rowspan=1 colspan=1>84.6</td></tr><tr><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>7.6%</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>4.3%</td></tr><tr><td rowspan=1 colspan=1>Method Comparison</td><td rowspan=1 colspan=3>Linear regression:y=1.03x-36.60, R=0.978</td><td rowspan=1 colspan=3>Linearity Regression:y=0.98x+45.2, R=0.973</td></tr><tr><td rowspan=1 colspan=1>Medical Decision Limits</td><td rowspan=1 colspan=3>No change.</td><td rowspan=1 colspan=3>1000, 1300 and 1600 nmol/L</td></tr><tr><td rowspan=1 colspan=1>Interference Study</td><td rowspan=1 colspan=3>7 Endogenous and 23 Exogenous weretested. Salicyclic acid at ≥ 1.3mmol/Lwas determined to interfere with LDL-P and Clopidogrel hydrogensulfate at≥ 95.7 μmol/L was determined tointerfere with LDL-P</td><td rowspan=1 colspan=3>5 Endogenous and 22 Exogenouswere tested, no interference wasfound.</td></tr><tr><td rowspan=1 colspan=1>Specimen Stability</td><td rowspan=1 colspan=3>Lipotube:Refrigerated Stability: 6 days</td><td rowspan=1 colspan=3>Lipotube:Refrigerated Stability: 5 days</td></tr></table>

Triglycerides Analytical Performance Summary   

<table><tr><td rowspan=1 colspan=1>.TG (mg/dL)</td><td rowspan=1 colspan=3>Vantera clinical analyzerfor use with theNMR LipoProfile test</td><td rowspan=1 colspan=3>Predicate Device k111516</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=3>1.1</td><td rowspan=1 colspan=3>1.4</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=3>2.4</td><td rowspan=1 colspan=3>2.6</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=3>4</td><td rowspan=1 colspan=3>2.6</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=3>5</td><td rowspan=1 colspan=3>1100</td></tr><tr><td rowspan=1 colspan=1>Linearity Regression</td><td rowspan=1 colspan=3>y=1.008x-0.3979</td><td rowspan=1 colspan=3>y=0.95x-12.21</td></tr><tr><td rowspan=1 colspan=1>Linearity R2</td><td rowspan=1 colspan=3>0.9999</td><td rowspan=1 colspan=3>0.999</td></tr><tr><td rowspan=1 colspan=1>Within-Run Precision</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>70.1</td><td rowspan=1 colspan=1>169.2</td><td rowspan=1 colspan=1>356.1</td><td rowspan=1 colspan=1>81.0</td><td rowspan=1 colspan=1>140.6</td><td rowspan=1 colspan=1>649.5</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Within-Lab Precision</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>166.3</td><td rowspan=1 colspan=1>352.2</td><td rowspan=1 colspan=1>78.4</td><td rowspan=1 colspan=1>145.4</td><td rowspan=1 colspan=1>624.6</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>3.92</td><td rowspan=1 colspan=1>9.36</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>15.4</td></tr><tr><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=1 colspan=1>Method Comparison</td><td rowspan=1 colspan=3>Linear regression:y=1.00x+0.92, R=0.998</td><td rowspan=1 colspan=3>Linear regression:y=1.00x+1.25, R=1.00</td></tr><tr><td rowspan=1 colspan=1>Medical Decision Limits</td><td rowspan=1 colspan=3>No change.</td><td rowspan=1 colspan=3>Normal (&lt;150)Borderline-High (150-199)High (200-499)Very High (500)</td></tr><tr><td rowspan=1 colspan=1>Interference Study</td><td rowspan=1 colspan=3>7 Endogenous and 23 Exogenous weretested, no interference was found.</td><td rowspan=1 colspan=3>5 Endogenous and 22 Exogenouswere tested, no interference wasfound except Ibuprofen may interferewith TG measurement at and above210μg/mL.</td></tr><tr><td rowspan=1 colspan=1>Specimen Stability</td><td rowspan=1 colspan=3>Lipotube:Refrigerated Stability: 6 days</td><td rowspan=1 colspan=3>Lipotube:Refrigerated Stability: 10 days</td></tr></table>

HDL-C Analytical Performance Summary   

<table><tr><td rowspan=1 colspan=1>HDL-C (mg/dL)</td><td rowspan=1 colspan=3>Vantera clinical analyzerfor use with theNMR LipoProfile test</td><td rowspan=1 colspan=3>Predicate Device k111516</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=3>2.7</td><td rowspan=1 colspan=3>4.3</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=3>3.5</td><td rowspan=1 colspan=3>5.2</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=3>4</td><td rowspan=1 colspan=3>5.2</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=3>7-140</td><td rowspan=1 colspan=3>7-140</td></tr><tr><td rowspan=1 colspan=1>Linearity Regression</td><td rowspan=1 colspan=3>y=1.049x-0.3459</td><td rowspan=1 colspan=3>y=1.004x-0.5956</td></tr><tr><td rowspan=1 colspan=1>Linearity R2</td><td rowspan=1 colspan=3>0.9961</td><td rowspan=1 colspan=3>0.9998</td></tr><tr><td rowspan=1 colspan=1>Within-Run Precision</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>29.1</td><td rowspan=1 colspan=1>51.1</td><td rowspan=1 colspan=1>86.9</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>54.9</td><td rowspan=1 colspan=1>95.1</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>1.43</td><td rowspan=1 colspan=1>2.29</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=1 colspan=1>Within-Lab Precision</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>Level 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>28.9</td><td rowspan=1 colspan=1>50.7</td><td rowspan=1 colspan=1>85.2</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>56.7</td><td rowspan=1 colspan=1>96.1</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1>Method Comparison</td><td rowspan=1 colspan=3>Linear regression:y=1.04x-1.20, R=0.989</td><td rowspan=1 colspan=3>Linear regression:y=1.00x+0.03, R=0.999</td></tr><tr><td rowspan=1 colspan=1>Medical Decision Limits</td><td rowspan=1 colspan=3>No change.</td><td rowspan=1 colspan=3>Low(&lt;40),High(≥60)</td></tr><tr><td rowspan=1 colspan=1>Interference Study</td><td rowspan=1 colspan=3>7 Endogenous and 23 Exogenous weretested, no interference was found.</td><td rowspan=1 colspan=3>5 Endogenous and 22 Exogenouswere tested, no interference wasfound.</td></tr><tr><td rowspan=1 colspan=1>Specimen Stability</td><td rowspan=1 colspan=3>Lipotube:Refrigerated Stability: 6 days</td><td rowspan=1 colspan=3>Lipotube:Refrigerated Stability: 10 days</td></tr></table>

# H. Performance Data - Non-Clinical:

Analytical Sensitivity

The analytical sensitivity of the NMR LipoProfile test measurements of LDL-P, HDL-C, and triglycerides was determined as the lowest concentration measurable with acceptable precision and accuracy. Limits of quantification (LoQ), Limit of Blank (LoB) and Limit of Detection (LoD) for LDL-P, HDL-C and Triglycerides following EP17-A are listed

# LDL-P

Five serum pools containing very low concentration were tested in replicates of 4 for 3 days. The Limit of Quantification (LoQ) was mathematically calculated for LDL-P by plotting the $\% \mathrm { C V }$ on the Y-axis against low concentration pools and determined to be: $\mathrm { L o Q } = 1 3 2 \mathrm { n m o l / L }$ .

Non-lipoprotein specimens were analyzed 60 consecutive times for 3 days. The Limit of Blank (LoB) was calculated non-parametrically for LDL-P and determined to be: $\mathrm { L o B } = 0 . 0 \ \mathrm { n m o l / L }$ .

Five serum pools containing very low concentration were tested in replicates of 4 for 3 days. The Limit of Detection (LoD) was calculated parametrically for LDL-P and determined to be: $\mathrm { L o D } = 4 0 . 7 \ \mathrm { n m o l / L }$ .

# HDL-C

Five serum pools containing very low concentration were tested in replicates of 4 for 3 days. The Limit of Quantification (LoQ) was mathematically calculated for HDL-C by plotting the $\% \mathrm { C V }$ on the $\mathrm { Y }$ -axis against low concentration pools and determined to be: $\mathrm { L o Q } = 4 ~ \mathrm { m g / d L }$ .

Non-lipoprotein specimens were analyzed 60 consecutive times for 3 days. The Limit of Blank (LoB) was calculated non-parametrically for HDL-C and determined to be: $\mathrm { L o B } = 2 . 7 ~ \mathrm { m g / d L }$ .

Five serum pools containing very low concentration were tested in replicates of 4 for 3 days. The Limit of Detection $\left( \mathrm { L o D } \right)$ was calculated parametrically for HDL-C and determined to be: $\mathrm { L o D } = 3 . 5 \mathrm { m g } / \mathrm { d L }$ .

# Triglycerides

Five serum pools containing very low concentration were tested in replicates of 4 for 3 days. The Limit of Quantification $\left( \mathrm { L o Q } \right)$ was mathematically calculated for Triglycerides by plotting the $\% C V$ on the $\mathrm { Y }$ -axis against low concentration pools and determined to be: $\mathrm { L o Q } = 4 ~ \mathrm { m g / d L }$ .

Non-lipoprotein specimens were analyzed 60 consecutive times for 3 days. The Limit of Blank (LoB) was calculated non-parametrically for Triglycerides and determined to be: $\mathrm { L o B } = 1 . 1 \ \mathrm { m g / d L }$ .

Five serum pools containing very low concentration were tested in replicates of 4 for 3 days. The Limit of Detection (LoD) was calculated parametrically for Triglycerides and determined to be: $\mathrm { L o D } = 2 . 4 ~ \mathrm { m g / d L }$ .

# Assay Precision

Within-run precision and within-laboratory precision were determined by testing 20 replicates of three patient serum pools in the same run and in 20 different runs over 20 days. The pools were analyzed according to EP-5A. The results of this testing are summarized below:

# Within-run Precision $\bf ( n { = } 2 0 )$

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Pool #1</td><td rowspan=1 colspan=3>Pool #2</td><td rowspan=1 colspan=3>Pool #3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LDL-P,nmol/L</td><td rowspan=1 colspan=1>842.6</td><td rowspan=1 colspan=1>48.5</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>1309.5</td><td rowspan=1 colspan=1>39.1</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1837.7</td><td rowspan=1 colspan=1>50.3</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>HDL-C,mg/dL</td><td rowspan=1 colspan=1>29.1</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>51.1</td><td rowspan=1 colspan=1>1.43</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>86.9</td><td rowspan=1 colspan=1>2.29</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Triglycerides,mg/dL</td><td rowspan=1 colspan=1>70.1</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>169.2</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>356.1</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.2</td></tr></table>

# Within-Laboratory Precision $( \mathbf { n } { = } 8 \mathbf { 0 } )$

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Pool #1</td><td rowspan=1 colspan=3>Pool #2</td><td rowspan=1 colspan=3>Pool #3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>LDL-P,nmol/L</td><td rowspan=1 colspan=1>988.6</td><td rowspan=1 colspan=1>52.20</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>1266.7</td><td rowspan=1 colspan=1>50.08</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1943.5</td><td rowspan=1 colspan=1>75.11</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>HDL-C,mg/dL</td><td rowspan=1 colspan=1>28.9</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>50.7</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>85.2</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Triglycerides,mg/dL</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>166.3</td><td rowspan=1 colspan=1>3.92</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>352.2</td><td rowspan=1 colspan=1>9.36</td><td rowspan=1 colspan=1>2.7</td></tr></table>

# Reproducibility

A reproducibility study was conducted in accordance to EP5-A2 at 3 sites incorporating five levels of serum panels at or around the medical decision limits. The panels were tested for 5 days, 6 runs per day, 2 replicates per run. The overall precision estimates are described below.

Premarket Notification 5 10(k) Vantera® Clinical Analyzer for use with NMR LipoProfile® test Section $6 - 5 1 0 ( \mathbf { k } )$ Summary   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>LDL-P (nmol/L)</td></tr><tr><td rowspan=1 colspan=1>Pool #</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>NMR 8001</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (nmol/L)</td><td rowspan=1 colspan=1>513.4</td><td rowspan=1 colspan=1>1129.4</td><td rowspan=1 colspan=1>1361.6</td><td rowspan=1 colspan=1>1957.7</td><td rowspan=1 colspan=1>3286.5</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD (nmol/L)</td><td rowspan=1 colspan=1>32.86</td><td rowspan=1 colspan=1>65.60</td><td rowspan=1 colspan=1>87.36</td><td rowspan=1 colspan=1>103.55</td><td rowspan=1 colspan=1>197.94</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>min (nmol/L)</td><td rowspan=1 colspan=1>431</td><td rowspan=1 colspan=1>988</td><td rowspan=1 colspan=1>1163</td><td rowspan=1 colspan=1>1641</td><td rowspan=1 colspan=1>2938</td></tr><tr><td rowspan=1 colspan=1>max (nmol/L)</td><td rowspan=1 colspan=1>573</td><td rowspan=1 colspan=1>1318</td><td rowspan=1 colspan=1>1510</td><td rowspan=1 colspan=1>2179</td><td rowspan=1 colspan=1>3636</td></tr><tr><td rowspan=1 colspan=1>median (nmol/L)</td><td rowspan=1 colspan=1>517</td><td rowspan=1 colspan=1>1127</td><td rowspan=1 colspan=1>1380.5</td><td rowspan=1 colspan=1>1962</td><td rowspan=1 colspan=1>3288.5</td></tr><tr><td rowspan=1 colspan=1>NMR 8002</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (nmol/L)</td><td rowspan=1 colspan=1>566.7</td><td rowspan=1 colspan=1>1260.6</td><td rowspan=1 colspan=1>1364.5</td><td rowspan=1 colspan=1>2050.7</td><td rowspan=1 colspan=1>3204.7</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD (nmol/L)</td><td rowspan=1 colspan=1>39.22</td><td rowspan=1 colspan=1>38.00</td><td rowspan=1 colspan=1>76.99</td><td rowspan=1 colspan=1>65.41</td><td rowspan=1 colspan=1>85.41</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=2 colspan=1>min (nmol/L)max (nmol/L)</td><td rowspan=1 colspan=1>457</td><td rowspan=1 colspan=1>1168</td><td rowspan=1 colspan=1>1155</td><td rowspan=1 colspan=1>1843</td><td rowspan=1 colspan=1>3036</td></tr><tr><td rowspan=1 colspan=1>660</td><td rowspan=1 colspan=1>1346</td><td rowspan=1 colspan=1>1555</td><td rowspan=1 colspan=1>2176</td><td rowspan=1 colspan=1>3419</td></tr><tr><td rowspan=1 colspan=1>median (nmol/L)</td><td rowspan=1 colspan=1>574</td><td rowspan=1 colspan=1>1258.5</td><td rowspan=1 colspan=1>1366</td><td rowspan=1 colspan=1>2050</td><td rowspan=1 colspan=1>3197</td></tr><tr><td rowspan=1 colspan=1>NMR 8003</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (nmol/L)</td><td rowspan=1 colspan=1>479.8</td><td rowspan=1 colspan=1>1156.3</td><td rowspan=1 colspan=1>1304.4</td><td rowspan=1 colspan=1>1980.6</td><td rowspan=1 colspan=1>3153.3</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD (nmol/L)</td><td rowspan=1 colspan=1>45.00</td><td rowspan=1 colspan=1>70.60</td><td rowspan=1 colspan=1>113.21</td><td rowspan=1 colspan=1>91.78</td><td rowspan=1 colspan=1>165.47</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>min (nmol/L)</td><td rowspan=1 colspan=1>388</td><td rowspan=1 colspan=1>871</td><td rowspan=1 colspan=1>891</td><td rowspan=1 colspan=1>1671</td><td rowspan=1 colspan=1>2561</td></tr><tr><td rowspan=1 colspan=1>max (nmol/l)</td><td rowspan=1 colspan=1>558</td><td rowspan=1 colspan=1>1255</td><td rowspan=1 colspan=1>1491</td><td rowspan=1 colspan=1>2136</td><td rowspan=1 colspan=1>3386</td></tr><tr><td rowspan=1 colspan=1>median (nmol/L)</td><td rowspan=1 colspan=1>485.5</td><td rowspan=1 colspan=1>1167</td><td rowspan=1 colspan=1>1337</td><td rowspan=1 colspan=1>1999</td><td rowspan=1 colspan=1>3192</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (nmol/L)</td><td rowspan=1 colspan=1>520.2</td><td rowspan=1 colspan=1>1182.1</td><td rowspan=1 colspan=1>1343.4</td><td rowspan=1 colspan=1>1996.2</td><td rowspan=1 colspan=1>3214.8</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>180</td></tr><tr><td rowspan=1 colspan=1>SD(nmol/L)</td><td rowspan=1 colspan=1>52.94</td><td rowspan=1 colspan=1>82.19</td><td rowspan=1 colspan=1>97.37</td><td rowspan=1 colspan=1>96.39</td><td rowspan=1 colspan=1>165.44</td></tr><tr><td rowspan=1 colspan=1>95% CI (nmol/L)</td><td rowspan=1 colspan=1>47.94- 59.11</td><td rowspan=1 colspan=1>74.48-91.68</td><td rowspan=1 colspan=1>88.22- 108.66</td><td rowspan=1 colspan=1>87.31- 107.59</td><td rowspan=1 colspan=1>149.93- 184.55</td></tr><tr><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>min (nmol/L)</td><td rowspan=1 colspan=1>388</td><td rowspan=1 colspan=1>871</td><td rowspan=1 colspan=1>891</td><td rowspan=1 colspan=1>1641</td><td rowspan=1 colspan=1>2561</td></tr><tr><td rowspan=1 colspan=1>max (nmol/L)</td><td rowspan=1 colspan=1>660</td><td rowspan=1 colspan=1>1346</td><td rowspan=1 colspan=1>1555</td><td rowspan=1 colspan=1>2179</td><td rowspan=1 colspan=1>3636</td></tr><tr><td rowspan=1 colspan=1>median (nmol/L)</td><td rowspan=1 colspan=1>491</td><td rowspan=1 colspan=1>1165</td><td rowspan=1 colspan=1>1330</td><td rowspan=1 colspan=1>2006</td><td rowspan=1 colspan=1>3179</td></tr></table>

Premarket Notification 510(kVantera® Clinical Analyzer for use with NMR LipoProfile® test Section $6 - 5 1 0 ( \mathbf { k } )$ Summary   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>HDL-C (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Pool #</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>NMR 8001</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean{mg/dL)</td><td rowspan=1 colspan=1>21.5</td><td rowspan=1 colspan=1>33.4</td><td rowspan=1 colspan=1>53.7</td><td rowspan=1 colspan=1>80.1</td><td rowspan=1 colspan=1>92.1</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD{(mg/dL)</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>1.81</td><td rowspan=1 colspan=1>3.70</td><td rowspan=1 colspan=1>2.61</td></tr><tr><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>min(mg/dL)</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>87</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)</td><td rowspan=1 colspan=1>21.5</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>78.5</td><td rowspan=1 colspan=1>92</td></tr><tr><td rowspan=1 colspan=1>NMR 8002</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>19.4</td><td rowspan=1 colspan=1>29.2</td><td rowspan=1 colspan=1>52.3</td><td rowspan=1 colspan=1>72.9</td><td rowspan=1 colspan=1>87.5</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>1.34</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>1.28</td></tr><tr><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>min(mg/dL)</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>NMR 8003</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>19.4</td><td rowspan=1 colspan=1>28.3</td><td rowspan=1 colspan=1>49.9</td><td rowspan=1 colspan=1>74.4</td><td rowspan=1 colspan=1>84.9</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>4.26</td><td rowspan=1 colspan=1>3.39</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>min (mg/dL)</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>72</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>89</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>86</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>20.1</td><td rowspan=1 colspan=1>30.3</td><td rowspan=1 colspan=1>52.0</td><td rowspan=1 colspan=1>75:8</td><td rowspan=1 colspan=1>88.2</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>180</td></tr><tr><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>2.45</td><td rowspan=1 colspan=1>4.56</td><td rowspan=1 colspan=1>3.91</td></tr><tr><td rowspan=1 colspan=1>95% Cl (mg/dL)</td><td rowspan=1 colspan=1>1.14- 1.41</td><td rowspan=1 colspan=1>2.35- 2.90</td><td rowspan=1 colspan=1>2.22- 2.73</td><td rowspan=1 colspan=1>4.14- 5.09</td><td rowspan=1 colspan=1>3.55- 4.36</td></tr><tr><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>min(mg/dL)</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>72</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>97</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>86</td></tr></table>

Premarket Notification 510(k) Vantera® Clinical Analyzer for use with NMR LipoProfile® test Section 6 - 510(k) Summary   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>TG (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Pool #</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>NMR 8001</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>66.1</td><td rowspan=1 colspan=1>70.3</td><td rowspan=1 colspan=1>133.5</td><td rowspan=1 colspan=1>153.5</td><td rowspan=1 colspan=1>343.3</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>1.84</td><td rowspan=1 colspan=1>2.15</td><td rowspan=1 colspan=1>4.35</td><td rowspan=1 colspan=1>5.92</td><td rowspan=1 colspan=1>7.09</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>min(mg/dL)</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>321</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>356</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>345</td></tr><tr><td rowspan=1 colspan=1>NMR 8002</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>70.3</td><td rowspan=1 colspan=1>74.6</td><td rowspan=1 colspan=1>141.4</td><td rowspan=1 colspan=1>169.7</td><td rowspan=1 colspan=1>361.1</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>1.59</td><td rowspan=1 colspan=1>3.03</td><td rowspan=1 colspan=1>3.10</td><td rowspan=1 colspan=1>5.01</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>min (mg/dL)</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>341</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>372</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>361</td></tr><tr><td rowspan=1 colspan=1>NMR 8003</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>66.5</td><td rowspan=1 colspan=1>70.4</td><td rowspan=1 colspan=1>134.3</td><td rowspan=1 colspan=1>160.9</td><td rowspan=1 colspan=1>339.8</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>3.44</td><td rowspan=1 colspan=1>4.77</td><td rowspan=1 colspan=1>7.10</td><td rowspan=1 colspan=1>18.50</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>min (mg/dL)</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>267</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>357</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>346</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>Panel 5</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>67.6</td><td rowspan=1 colspan=1>71.8</td><td rowspan=1 colspan=1>136.4</td><td rowspan=1 colspan=1>161.4</td><td rowspan=1 colspan=1>348.0</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>178</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>180</td></tr><tr><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>2.76</td><td rowspan=1 colspan=1>3.21</td><td rowspan=1 colspan=1>5.41</td><td rowspan=1 colspan=1>8.66</td><td rowspan=1 colspan=1>14.99</td></tr><tr><td rowspan=1 colspan=1>95% Cl (mg/dL)</td><td rowspan=1 colspan=1>2.50-3.08</td><td rowspan=1 colspan=1>2.91- 3.59</td><td rowspan=1 colspan=1>4.90- 6.03</td><td rowspan=1 colspan=1>7.75- 9.66</td><td rowspan=1 colspan=1>13.59- 16.72</td></tr><tr><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>min(mg/dL)</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>267</td></tr><tr><td rowspan=1 colspan=1>max (mg/dL)</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>372</td></tr><tr><td rowspan=1 colspan=1>median (mg/dL)]</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>344</td></tr></table>

# Linearity

Three serum pools were prepared from patient specimens with low, medium and high values of LDL-P, HDL-C and Triglycerides as determined by NMR LipoProfile test. Each were mixed and diluted in different proportions to produce eleven (for LDL-P) or Twelve (12) (TG and HDL-C) different samples with widely varying target concentrations. Mean values from analysis of four replicates of each pool were compared to the expected target values to determine the percent bias for each sample. The serum pools were analyzed according to EP6-A. Tables and regression plots of the linearity data for LDL-P, HDL-P and Triglycerides are given below:

LDL-P Measuring Range: 300-3500 nmol/L   

<table><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Targetvalue</td><td rowspan=1 colspan=1>225.4</td><td rowspan=1 colspan=1>263.375</td><td rowspan=1 colspan=1>673.75</td><td rowspan=1 colspan=1>1039.25</td><td rowspan=1 colspan=1>1222</td><td rowspan=1 colspan=1>1473.28</td><td rowspan=1 colspan=1>1770.25</td><td rowspan=1 colspan=1>2291.41</td><td rowspan=1 colspan=1>2968.22</td><td rowspan=1 colspan=1>3645.03</td><td rowspan=1 colspan=1>4321.84</td></tr><tr><td rowspan=1 colspan=1>ObservedMean</td><td rowspan=1 colspan=1>248.8</td><td rowspan=1 colspan=1>243.8</td><td rowspan=1 colspan=1>682.0</td><td rowspan=1 colspan=1>1115.0</td><td rowspan=1 colspan=1>1285.8</td><td rowspan=1 colspan=1>1402.3</td><td rowspan=1 colspan=1>1829.8</td><td rowspan=1 colspan=1>2437.5</td><td rowspan=1 colspan=1>3032.3</td><td rowspan=1 colspan=1>3644.3</td><td rowspan=1 colspan=1>4442.8</td></tr><tr><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>-7.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>-4.8</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.8 .</td></tr></table>

![](images/ca09738a542cfc35c5c8e2a25cbb6d670cf1255e6122f472f1aaf295170f38de.jpg)  
$\overline { { { \bf Y } { = } { 1 . \bf 0 1 9 3 x } + 7 . 8 2 2 6 , \mathrm { R } } } ^ { 2 } = { \bf 0 . 9 9 4 9 }$

# HDL-C Measuring Range: 7-140 mg/dL

<table><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Targetvalue</td><td rowspan=1 colspan=1>6.13</td><td rowspan=1 colspan=1>21.44</td><td rowspan=1 colspan=1>28.19</td><td rowspan=1 colspan=1>35.56</td><td rowspan=1 colspan=1>42.94</td><td rowspan=1 colspan=1>50.31</td><td rowspan=1 colspan=1>72.75</td><td rowspan=1 colspan=1>110.25</td><td rowspan=1 colspan=1>147.75</td></tr><tr><td rowspan=1 colspan=1>ObservedMean</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>22.50</td><td rowspan=1 colspan=1>29.25</td><td rowspan=1 colspan=1>36.25</td><td rowspan=1 colspan=1>43.25</td><td rowspan=1 colspan=1>50.75</td><td rowspan=1 colspan=1>81.50</td><td rowspan=1 colspan=1>117.25</td><td rowspan=1 colspan=1>151.50</td></tr><tr><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>2.5</td></tr></table>

![](images/9fae3061ea26d13f93a94b47d5cbb8ab7d46199eac8b821741994c4ecd188112.jpg)

Y=1.0486x -0.3459, $\overline { { { \bf R } } } ^ { 2 } = { \bf 0 } . 9 9 6 1$

Triglycerides Measuring Range: 5-1100 mg/dL   

<table><tr><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8.</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Target value</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>29.0</td><td rowspan=1 colspan=1>82.5</td><td rowspan=1 colspan=1>134.6</td><td rowspan=1 colspan=1>178.1</td><td rowspan=1 colspan=1>221.5</td><td rowspan=1 colspan=1>308.4</td><td rowspan=1 colspan=1>531.0</td><td rowspan=1 colspan=1>802.6</td><td rowspan=1 colspan=1>1074.2</td><td rowspan=1 colspan=1>1345.7</td></tr><tr><td rowspan=1 colspan=1>Observedaverage</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>26.3</td><td rowspan=1 colspan=1>84.5</td><td rowspan=1 colspan=1>135.0</td><td rowspan=1 colspan=1>177.8</td><td rowspan=1 colspan=1>219.3</td><td rowspan=1 colspan=1>306.0</td><td rowspan=1 colspan=1>536.0</td><td rowspan=1 colspan=1>816.8</td><td rowspan=1 colspan=1>1079.0</td><td rowspan=1 colspan=1>1356.3</td></tr><tr><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>43.1</td><td rowspan=1 colspan=1>31.7</td><td rowspan=1 colspan=1>19.2</td><td rowspan=1 colspan=1>-9.5</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>-0.2</td><td rowspan=1 colspan=1>-1.0</td><td rowspan=1 colspan=1>-0.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8</td></tr></table>

![](images/67d92ccc8258e214c15d4f3fff97e51b72ecb75c4641b19bde9014f9e9d141c8.jpg)  
Y=1.008x - 0.3979, $\widetilde { { \mathbf { R } } } ^ { 2 } = { \mathbf { 0 } } . 9 9 9 9 9$

# Reportable Range

The following are the reportable ranges for LDL-P, HDL-C and Triglycerides:

<table><tr><td rowspan=1 colspan=1>LDL-P</td><td rowspan=1 colspan=1>300 - 3500 nmol/L</td></tr><tr><td rowspan=1 colspan=1>HDL-C</td><td rowspan=1 colspan=1>7- 140 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>5- 1100 mg/dL</td></tr></table>

Traceability, Stability, Assigned values (controls, calibrators)

The NMR Reference Standard

The NMR Reference Standard, TMA (Trimethylacetic acid, Sodium salt), is used as the NMR calibrator for the Vantera Clinical Analyzer. TMA is used routinely as a calibrator once daily during instrument startup to establish daily normalization factors. It also serves as a quality assessment tool to ensure quality NMR spectra are produced by the NMR analyzer.

The stability of the TMA calibrator material and storage conditions was evaluated for a period of 18 months across multiple NMR Analyzers. It was stored at room temperature and refrigerated at $4 \%$ , in glass bottles and plastic bottles. TMA samples were evaluated for TMA signal methyl integrals every other month. The quality of the TMA spectra was not affected by the storage conditions during the study. The NMR Reference Standard is stable for 18 months in either glass or plastic bottle regardless of room temperature or refrigerated storage.

Liquichek™ Lipids Control

Liquichek™ Lipids Control material for LDL-P is frozen human serum in two pools, Level 1 and Level 2, prepared and packaged by Bio-Rad Laboratories. To assign values, new lots of Liquicheck™ Lipids Control material are run on 3 qualified Vantera Clinical Analyzers in house for 3 days. Means, Standard Deviations and $\%$ CVs are computed and new values are assigned.

T Liuicc Lipi Cnolatal s abl   an v over this period was estimated to be less than $0 . 6 \%$ for LDL-P.

# Interfering Substances

Endogenous substances normally found in blood and exogenous substances (common and prescription drugs) were evaluated for potential interference with the NMR LipoProfile® test by LipoScience. Seven endogenous agents and twenty three drugs were screened for potential interfering effects to NMR LipoProfile test using concentrations in accordance to CLSI EP7-A2 guidelines.

<table><tr><td colspan="2">Endogenous</td><td colspan="3">Exogenous (OTC drugs, etc.)</td></tr><tr><td>Potential</td><td>Test</td><td>Test</td><td></td><td>Test</td></tr><tr><td>Interferent Hemoglobin</td><td>Concentration 0.5 g/dL</td><td>Potential Interferent Acetaminophen</td><td>Concentration 1324 μmol/L</td><td>Potential Interferent Metformin</td><td>Concentration 3.62 mmol/L</td></tr><tr><td></td><td></td><td></td><td></td><td>Hydrochloride</td><td></td></tr><tr><td>Bilirubin, unconj.</td><td>342 μmol/L 20 mg/dL</td><td>Acetylsalicylic acid</td><td>3.62 mmol/L</td><td>Metoprolol tartrate</td><td>18.7 μmol/L</td></tr><tr><td>Creatinine</td><td>442 μmol/L 5</td><td>Atorvastatin</td><td>600 μg Eq/L</td><td>Naproxen Sodium</td><td>2170 μmol/L</td></tr><tr><td>I Urea</td><td>mg/dL 42.9 mmol/L</td><td>Clopidogrel</td><td>95.7 μmol/L</td><td>Nicotinic Acid</td><td>8.28 mmol/L</td></tr><tr><td>Uric acid</td><td>260 mg/dL 1.4 mmol/L</td><td>hydrogensulfate** Enalaprilat Dihydrate</td><td>0.86 μmol/L</td><td>Sodium salt Nifedipine</td><td>1156 nmol/L</td></tr><tr><td>Protein</td><td>23.5 mg/dL 6 g/dL60g/L</td><td>Fenofibrate</td><td>125 μmol/L</td><td>Pioglitazone</td><td></td></tr><tr><td>(albumin) Bilirubin, conj</td><td>342 μmol/L</td><td></td><td></td><td>hydrochloride</td><td>152.7μmol/L</td></tr><tr><td></td><td>28.9 mg/dL</td><td>Furosemide</td><td>181 μmol/L</td><td>Piroxicam</td><td>181 μmol/L</td></tr><tr><td></td><td></td><td>Glipizide</td><td>4.48 μmol/L</td><td>Pravastatin</td><td>107.5 μmol/L</td></tr><tr><td></td><td></td><td>Hydralazine hydrochloride</td><td>915.4 μmol/L</td><td>Salicylic Acid*</td><td>1.3 mmol/L</td></tr><tr><td></td><td></td><td>Heparin</td><td>3000U/L</td><td>Simvastatin</td><td>114.7 μmol/L</td></tr><tr><td></td><td></td><td>Ibuprofen Sodium</td><td>2425 μmol/L</td><td></td><td></td></tr><tr><td></td><td></td><td>salt Isosorbide dinitrate</td><td>636 nmol/L</td><td></td><td></td></tr><tr><td></td><td></td><td>Menhaden oil (Fish</td><td>2.4 mg/mL</td><td></td><td></td></tr><tr><td></td><td></td><td>Oil)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>*Salicyclic acid at ≥ 1.3mmol/L was determined to interfere with LDL-P **Clopidogrel hydrogensulfate at ≥ 95.7 μmol/L was determined to interfere with LDL-P</td><td></td><td></td><td></td></tr></table>

# H. Method Comparison - Non-Clinical:

Method Comparison - LDL-P

Method comparison was evaluated by using serum samples across the reportable range of the NMR LipoProfile test for LDL-P on the Vantera Clinical Analyzer. LDL-P concentrations ranged from 303.0 to 3505.0nmol/L.

![](images/5debacd1dd068825fb8533cb3a9d967e6ba042260b40d0e9cea0f29b901eb080.jpg)  
Vantera vs. NMR Profiler LDL-P Linear Regression Plot (n=1483)

Y=1.03x - 36.60 r=0.978

Method Comparison  HDL-C

Method comparison was evaluated by using serum samples across the reportable range of the NMR LipoProfile test for HDL-C on the Vantera Clinical Analyzer. HDL-C concentrations ranged from 7.0 to $1 3 2 { \mathrm { m g / d L } }$ .

![](images/60832502c733a84e36bada16c4dfd613140209791fa49e37b074d23a5c675132.jpg)  
Vantera vs. NMR Profiler HDL-C Linear Regression Plot $\bf \left( n { = } 1 5 1 8 \right)$

$$
\mathbf { Y } { = } 1 . 0 4 \mathbf { x } - 1 . 2 \mathbf { 0 } \mathbf { r } { = } \mathbf { 0 } . 9 8 9
$$

# Method comparison Triglycerides

Method comparison was evaluated by using serum samples across the reportable range of the NMR LipoProfile test for Triglycerides on the Vantera Clinical Analyzer. Triglyceride concentrations ranged from 18.0 to $\mathrm { 1 0 9 5 . 0 \ m g / d L }$ .

# Vantera vs. NMR Profiler TG Linear Regression Plot $\bf ( n { = } 1 5 2 0 )$

![](images/2c48dcea38c1f73b633126fa98d81f85213cf5d856d11bdcd7ff86d04b0bad75.jpg)

# K. Standard/Guidance Documents Referenced (if applicable):

Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.

Class II Special Controls Guidance Document: Instrumentation for Clinical Multiplex Test Systems

EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods; Approves Guideline - Second Edition

EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline

EP7-A2: Interference Testing in Clinical Chemistry; Approved Guideline  Second Edition

EP9-A2: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline - Second Edition

EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantification; Approved Guideline

EP14-A2: Evaluation of Matrix Effects: Approved Guideline  Second Edition

C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical

C53-A: Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Approved Guideline

IEC 61010-1:2001. $\cdot 2 ^ { \mathfrak { n } \mathtt { d } }$ Edition: Safety requirements for electrical equipment for measurement, control and laboratory use Part: General requirements

This device has not been tested by the Cholesterol Reference Method Laboratory Network.

# M. Clinical Studies:

a. Clinical Sensitivity: Not Applicable   
b. Clinical specificity: Not Applicable

c.Other clinical supportive data (when a. and b. are not applicable):

Not Applicable

1. Clinical cut-off: Not Applicable

2. Expected values/Reference range:

In order to determine the distribution of LDL-P levels expected in a representative sampling of the general population, serum·samples $( \mathfrak { n } ^ { = 4 5 2 ) }$ were analyzed from apparently healthy men $\scriptstyle ( \ n = 1 5 8 )$ and women $\scriptstyle ( { \mathfrak { n } } = 2 9 4 )$ (ranging from 18 to 84 years). The following table provides the concentrations of LDL-P by percentile in this reference population:

Distribution of LDL-P Observed in a Reference Population   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>All(n=452)</td><td rowspan=1 colspan=1>Men(n=158)</td><td rowspan=1 colspan=1>Women(n=294)</td><td rowspan=1 colspan=1>All(n=452)</td><td rowspan=1 colspan=1>Men(n=158)</td><td rowspan=1 colspan=1>Women(n=294)</td></tr><tr><td rowspan=1 colspan=1>Percentile</td><td rowspan=1 colspan=1>LDL-P(nmol/L)</td><td rowspan=1 colspan=1>LDL-P(nmol/L)</td><td rowspan=1 colspan=1>LDL-P(nmol/L)</td><td rowspan=1 colspan=1>LDL-C(mg/dL)</td><td rowspan=1 colspan=1>LDL-C(mg/dL)</td><td rowspan=1 colspan=1>LDL-C(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>539</td><td rowspan=1 colspan=1>528</td><td rowspan=1 colspan=1>542</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>643</td><td rowspan=1 colspan=1>713</td><td rowspan=1 colspan=1>638</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>784</td><td rowspan=1 colspan=1>883</td><td rowspan=1 colspan=1>749</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>83</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>909</td><td rowspan=1 colspan=1>1004</td><td rowspan=1 colspan=1>863</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1009</td><td rowspan=1 colspan=1>1087</td><td rowspan=1 colspan=1>970</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>1127</td><td rowspan=1 colspan=1>1241</td><td rowspan=1 colspan=1>1070</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1248</td><td rowspan=1 colspan=1>1366</td><td rowspan=1 colspan=1>1202</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>115</td></tr><tr><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>1396</td><td rowspan=1 colspan=1>1505</td><td rowspan=1 colspan=1>1322</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>124</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1572</td><td rowspan=1 colspan=1>1676</td><td rowspan=1 colspan=1>1482</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>136</td></tr><tr><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>1894</td><td rowspan=1 colspan=1>1941</td><td rowspan=1 colspan=1>1818</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>161</td><td rowspan=1 colspan=1>151</td></tr><tr><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>2047</td><td rowspan=1 colspan=1>2169</td><td rowspan=1 colspan=1>1986</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>169</td></tr></table>

Based on the recommendations from a National Lipids Association expert panel, suggested reference values are provided in Table 2. The recommendation by the NLA has not been validated by a clinical study. Each laboratory should verify the validity of these reference values for the population it serves.

Recommended LDL-P Reference Values   

<table><tr><td rowspan=1 colspan=4>LDL-P, nmol/L</td></tr><tr><td rowspan=1 colspan=4>Classification</td></tr><tr><td rowspan=2 colspan=1>Low / Normal</td><td rowspan=1 colspan=2>Intermediate</td><td rowspan=2 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>Moderate</td><td rowspan=1 colspan=1>Borderline High</td></tr><tr><td rowspan=1 colspan=1>&lt;1000</td><td rowspan=1 colspan=1>1000-1299</td><td rowspan=1 colspan=1>1300-1599</td><td rowspan=1 colspan=1>≥ 1600</td></tr></table>

# HDL Cholesterol and Triglycerides

The following reference values for patient classification have been recommended by the NCEP and Adult Treatment Panel III Guidelines for HDL cholesterol and triglycerides for the assessment and management of CVD risk. Each laboratory should verify the validity of these reference values for the population it serves.

<table><tr><td rowspan=1 colspan=2>HDL Cholesterol, mg/dL</td></tr><tr><td rowspan=1 colspan=2>Classification</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>&lt;40</td><td rowspan=1 colspan=1>≥60</td></tr></table>

<table><tr><td rowspan=1 colspan=4>Triglycerides, mg/dL</td></tr><tr><td rowspan=1 colspan=4>Classification</td></tr><tr><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>BorderlineHigh</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>Very High</td></tr><tr><td rowspan=1 colspan=1>&lt;150</td><td rowspan=1 colspan=1>150-199</td><td rowspan=1 colspan=1>200-499</td><td rowspan=1 colspan=1>≥500</td></tr></table>

# O. System Description:

1. Modes of Operation:

The Vantera Clinical Analyzer is a $4 0 0 \mathrm { M H z }$ proton nuclear magnetic resonance spectrometer.

2 Software:

The FDA has reviewed the applicant's Hazard Analysis and software development process for this line of product type:

Yes No

3. Specimen Identification:

Bar code of source tube

4. Specimen Sampling and Handling:

The processing of specimens on the Vantera Clinical Analyzer starts with their placement on the system. The user places serum or plasma specimen tubes in racks, and then places the racks on the system. After reading the bar code on a specimen tube, the system schedules the test or tests to be performed. The specimen is then aliquoted by the Metering Arm and is transferred to a dilution cup. Samples are prepared by diluting 2-fold (1:1) with specimen Diluent 1 performed by the Metering Arm assembly.

# 5. Calibration:

The instrument is calibrated with an aqueous solution of Trimethyl Acetate (TMA) as a disodium salt $( 1 5 . 0 \mathrm { m M } )$ containing $\mathrm { N a } _ { 2 } \mathrm { E D T A }$ $( 5 . 0 \mathrm { m M } )$ $\mathrm { C a C l } _ { 2 }$ (3.0 mM), KCI $1 2 0 \mathrm { m M } )$ $\mathrm { D } _ { 2 } 0 ~ 1 0 \% ~ \mathrm { v } / \mathrm { v }$

# 6Quality Control:

It is recommended that two levels of quality control materials are tested in the same manner as patient samples, before or during patient sample processing for each analyte being tested. To verify system performance, analyze control materials:

After calibration

According to federal, state or local regulations or at least once every day when patient testing is being performed.

Refer to the Liquichek™M Lipids Controls LDL-P value assignment card for LDLP Target Ranges. It is recommended that each laboratory establish its own mean and acceptance range for each new lot of controls. Patient results should not be reported if the Quality Control values are not within the expected range.

Real-time quality control data indicate that stability for BioRad Liquichek Lipids controls is at least 6 months. A stability study is currently ongoing to extend the dating for the Bio-Rad Liquichek Lipids Controls.

# P. Other Supportive Instrument Performance Characteristics Data Not Covered In the "Performance Characteristics" Section above:

Not Applicable

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

LipoScience, Inc. c/o Suzette Warner 2500 Sumner Boulevard Raleigh, NC 27616

Re: k113830 Trade Name: Vantera $\textsuperscript { \textregistered }$ Clinical Analyzer; NMR LipoProfile $\textsuperscript { \textregistered }$ test on Vantera Clinical Analyzer Regulation Number: 21 CFR $\ S 8 6 2 . 2 5 7 0$ Regulation Name: Instrumentation for clinical multiplex test systems Regulatory Class: Class II Product Codes: NSU, MRR, LBS, CDT Dated: July 27, 2012 Received: July 30, 2012

Dear Ms. Warner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal'statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/b61aa047a74f7af095fb01cd097e7075e88b292048f51df2c4abc5de1f2107a2.jpg)

Coupney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indication for Use

510(k) Number (ifknown): K113830

Device Name: Vantera® Clinical Analyzer

# Indications for Use:

The Vantera® Clinical Analyzer is an automated laboratory test analyzer which measures the $4 0 0 ~ \mathrm { M H z }$ proton nuclear magnetic resonance (NMR) spectrum of clinical samples to produce signal amplitudes, converting these signal amplitudes to analyte concentration. The device includes a 400 MHz NMR spectrometer and software to analyze digitized spectral data. This instrumentation is intended to be used with NMR based assays to detect multiple analytes from clinical samples.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/766e2d684f6965f3fb0c8f9f67dc2b18bf1aff13ff9f34fef26208cccbc1fc5d.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Page 1 of 2

# Indication for Use

510(k) Number (if known):

# Device Name:

# NMR LipoProfile® test on Vantera® Clinical Analyzer

# Indications for Use:

The NMR LipoProfile® test, when used with the Vantera® Clinical Analyzer, an automated NMR spectrometer, measures lipoprotein particles to quantify LDL particle number (LDL-P), HDL cholesterol (HDL-C), and triglycerides in human serum and plasma using nuclear magnetic resonance (NMR) spectroscopy. LDL-P and these NMRderived concentrations of HDL-C and triglycerides are used in conjunction with other lipid measurements and clinical evaluation to aid in the management of lipoprotein disorders associated with cardiovascular disease.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/29f92ef8c5dc0e51fea06d1be37b3b8157e11391e118d46a0fc2aac7addcf327.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k).

PageLof 2